EPS for aTyr Pharma, Inc. (LIFE) Expected At $-0.39 on May, 10

May 3, 2018 - By Daniel Cummings

aTyr Pharma, Inc. (NASDAQ:LIFE) Corporate Logo

aTyr Pharma, Inc. (NASDAQ:LIFE)’s earnings report is anticipated by WallStreet on May, 10, Faxor reports. Analysts expect change of 30.36 % or $0.17 from previous year’s $-0.56 EPS compared to current’s $-0.39 EPS. 0.00 % EPS growth is what Wall Street’s sees after $-0.39 reported EPS last quarter. The stock decreased 2.13% or $0.05 during the last trading session, reaching $2.3.aTyr Pharma, Inc. has volume of 3 shares. Since May 3, 2017 LIFE has declined 19.01% and is downtrending. LIFE underperformed by 30.56% the S&P 500.

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Coverage

A total of 2 analysts rate aTyr Pharma (NASDAQ:LIFE) as follows: 0 “Buy”, 0 “Hold” and 2 “Sell”. Тherefore 0 are bullish. (NASDAQ:LIFE) has 3 ratings reports on May 3, 2018 according to StockzIntelligence. On Wednesday, February 14 J.P. Morgan downgraded the shares of LIFE in report to “Sell” rating. On Wednesday, February 14 the stock of aTyr Pharma, Inc. (NASDAQ:LIFE) earned “Underweight” rating by JP Morgan.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases.The company has $68.54 million market cap. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy.Last it reported negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.

aTyr Pharma, Inc. (NASDAQ:LIFE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: